Article Figures & Data
Tables
- TABLE 1
Rate of Recurrent Disease, Persistent Disease, and Death after 131I Therapy in Intermediate-Risk Patients
Population 1.11–1.85 GBq ≥3.7 GBq* P All patients (n = 225) 24% (20/85) 28% (39/140) Not significant T3N0-X (n = 97) 21% (9/43) 20% (11/54) Not significant T1–2N1 and T1–2N0 with aggressive histology (n = 54) 21% (4/19) 26% (9/35) Not significant T3N1 (n = 74) 30% (7/23) 37% (19/51) Not significant ↵* No mean or median was given. Similar results were presented for remission, biochemical disease, and metastatic disease for the first therapy.
